Literature DB >> 9113517

The TMC Worldwide Gene Therapy Enrollment Report, end 1996.

T Marcel1, J D Grausz.   

Abstract

Entities:  

Mesh：

Year:  1997        PMID： 9113517     DOI： 10.1089/hum.1997.8.6-775

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  9 in total

1.  The 17 nucleotides downstream from the env gene stop codon are important for murine leukemia virus packaging.

Authors:  S S Yu; J M Kim; S Kim
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Unusual mechanical stability of a minimal RNA kissing complex.

Authors:  Pan T X Li; Carlos Bustamante; Ignacio Tinoco
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-16       Impact factor: 11.205

3.  A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy.

Authors:  G Schoofs; T J Monica; J Ayala; J Horwitz; T Montgomery; G Roth; F J Castillo
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

4.  Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber.

Authors:  V Legrand; D Spehner; Y Schlesinger; N Settelen; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 5.  Recent advances in the treatment of malignant melanoma with gene therapy.

Authors:  E M Hersh; A T Stopeck
Journal:  Mol Med       Date:  1997-10       Impact factor: 6.354

6.  Development of improved adenosine deaminase retroviral vectors.

Authors:  M Onodera; D M Nelson; A Yachie; G J Jagadeesh; B A Bunnell; R A Morgan; R M Blaese
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo.

Authors:  M Ohashi; F Kanai; H Ueno; T Tanaka; K Tateishi; T Kawakami; Y Koike; T Ikenoue; Y Shiratori; H Hamada; M Omata
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

8.  TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer.

Authors:  Shan-Yu Guo; Qin-Long Gu; Zheng-Gang Zhu; He-Qun Hong; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

9.  Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.

Authors:  S S Yoon; N M Carroll; E A Chiocca; K K Tanabe
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.